Our Statement on COVID-19

April 23, 2021

At Agios, the health of our employees, our communities and the patients we serve is our top priority.

Since the start of the COVID-19 pandemic in the U.S. in March 2020, we have implemented precautionary measures, including suspending all international and domestic business travel and requiring the majority of our employees to work from home, to reduce the likelihood of exposure or transmitting the virus to others. Our culture of flexibility – already a pillar before COVID-19 – has helped us shift in this environment and continue our important work with minimal disruption. While taking these precautions, we have activated business continuity plans to additionally minimize disruptions to our business and continue to serve the patients who are counting on us.

We do not know the extent to which COVID-19 will continue to spread and impact society. We will continue to monitor the situation and evaluate the potential impact to our business.

Our Team and Communities

  • Most of our employees are working from home to reduce the likelihood of exposure or transmitting the virus to others. Starting in June 2020, we have led a deliberate, phased approach to returning to on-site work under a set of operating procedures designed to protect the health and wellbeing of our team and communities while considering the productivity of our employees.
    • To date, only employees who have critical on-site work – such as those who work in our labs – have returned regularly to our Cambridge headquarters. Since the fall of 2020, a limited number of other employees have been able to schedule use of office space in advance (to limit numbers and assist with contact tracing). We hope to provide more regular access to our office beginning in the summer or fall depending several factors, including the level of vaccination for and prevalence of COVID-19.
    • We have implemented many measures to ensure the safety of those who need to be on-site, including daily health screenings, requiring the use of masks, clear signage to ensure social distancing can be maintained, single occupancy restrooms, scheduling in-person work and providing support to enable employees to commute without using public transit.
    • In addition, as local regulations and institutions have allowed, some of our field team members have begun to interact with their customers in person again.
  • We have made these decisions based on a number of considerations, including local and national public health guidelines, updated data on COVID-19 cases, employee input on their preferences and our desire to reduce risk for our employees and communities while continuing to advance our important work on behalf of patients.

Clinical Trial Patients and Investigators

  • Inventory of our investigational medicines is in place to support ongoing and planned global clinical trials.
  • Because hospitals globally shifted resources to treat patients with COVID-19 at the beginning of the pandemic, Agios is experiencing some delays in clinical program timelines based on anticipated challenges related to data collection, access to trial sites and patient enrollment.
  • In February 2020, Agios established a clinical trial task force to ensure the safety of patients in its clinical trials and to support patients on a case-by-case basis to enable their continued participation in the studies. Where appropriate, Agios has instituted home visits, telemedicine approaches, the use of local laboratories and courier shipments of investigational medicines.
  • We are continuing to monitor each of our clinical trials and are taking measures to minimize disruption.
  • If you have any questions or concerns, please consult with the physicians at your clinical trial site.